Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
15
BIOLQ Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
-19.44%
Day range:
$0.0091 - $0.0120
52-week range:
$0.0040 - $0.0960
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
--
Volume:
77.4K
Avg. volume:
57.9K
1-year change:
-89.97%
Market cap:
$333K
Revenue:
$49.2M
EPS (TTM):
-$2.04
Analysts' Opinion
-
Consensus RatingBiolase has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.2000, Biolase has an estimated upside of 21878.02% from its current price of $0.0091.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.4000 representing 100% downside risk from its current price of $0.0091.
Fair Value
-
According to the consensus of 2 analysts, Biolase has 21878.02% upside to fair value with a price target of $1.2000 per share.
BIOLQ vs. S&P 500
-
Over the past 5 trading days, Biolase has underperformed the S&P 500 by -6.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biolase does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biolase revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Biolase reported revenues of $10.9M.
Earnings Growth
-
Biolase has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Biolase reported earnings per share of -$0.04.
Enterprise value:
14.5M
EV / Invested capital:
--
Price / LTM sales:
0.00x
EV / EBIT:
--
EV / Revenue:
0.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$15.9M
Return On Assets:
-48.28%
Net Income Margin (TTM):
-34.84%
Return On Equity:
-21668.17%
Return On Invested Capital:
-129.74%
Operating Margin:
-6.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $46.8M | $49.7M | $46M | $10.9M | $10.9M | |
| Gross Profit | $17.2M | $16.8M | $15.9M | $3.7M | $4.4M | |
| Operating Income | -$21.2M | -$21.3M | -$13.5M | -$3.7M | -$695K | |
| EBITDA | -$21.7M | -$19.6M | -$11M | -$3.4M | -$166K | |
| Diluted EPS | -$358.34 | -$182.32 | -$2.04 | -$10.35 | -$0.04 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $36M | $52.7M | $33.9M | $27.8M | $19.4M | |
| Total Assets | $42M | $58.5M | $42.9M | $38.7M | $27.2M | |
| Current Liabilities | $21.4M | $13.5M | $13.8M | $19.8M | $30.9M | |
| Total Liabilities | $28.1M | $28.2M | $29M | $38.4M | $32.5M | |
| Total Equity | $13.9M | $30.3M | $13.9M | $332K | -$5.2M | |
| Total Debt | $16.1M | $13.5M | $12.8M | $14.1M | $17.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$24.3M | -$17.4M | -$13.4M | -$2.6M | -$4.5M | |
| Cash From Investing | -$3.6M | -$1.6M | $288K | -$182K | $34K | |
| Cash From Financing | $4.7M | $16.5M | $8.6M | $3.8M | $2.5M | |
| Free Cash Flow | -$27.9M | -$19M | -$13.7M | -$2.8M | -$4.5M | |
BIOLQ
Sector
Market Cap
$333K
$34.4M
Price % of 52-Week High
9.48%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-89.97%
-37.36%
Beta (5-Year)
0.028
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0096
200-day SMA
Sell
Level
$0.0115
Bollinger Bands (100)
Sell
Level
0.0104 - 0.0104
Chaikin Money Flow
Sell
Level
-348.5M
20-day SMA
Sell
Level
$0.0105
Relative Strength Index (RSI14)
Sell
Level
43.7651
ADX Line
Buy
Level
12.4303
Williams %R
Buy
Level
-86.0465
50-day SMA
Sell
Level
$0.0104
MACD (12, 26)
Sell
Level
-0.0004
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
840.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.7069)
Sell
CA Score
(Annual)
Level (-4.1866)
Buy
Beneish M-Score
(Annual)
Level (-3.4791)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.4)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Stock Forecast FAQ
In the current month, BIOLQ has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BIOLQ average analyst price target in the past 3 months is $1.2000.
-
Where Will Biolase Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biolase share price will rise to $1.2000 per share over the next 12 months.
-
What Do Analysts Say About Biolase?
Analysts are divided on their view about Biolase share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biolase is a Sell and believe this share price will drop from its current level to $0.4000.
-
What Is Biolase's Price Target?
The price target for Biolase over the next 1-year time period is forecast to be $1.2000 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is BIOLQ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biolase is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of BIOLQ?
You can purchase shares of Biolase via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biolase shares.
-
What Is The Biolase Share Price Today?
Biolase was last trading at $0.0100 per share. This represents the most recent stock quote for Biolase. Yesterday, Biolase closed at $0.0091 per share.
-
How To Buy Biolase Stock Online?
In order to purchase Biolase stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
